Upon completion of this activity, participants should be able to: (1) Select therapy for bladder cancer including non-muscle-invasive, muscle-invasive, locally advanced, and metastatic disease taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference; (2) Plan individualized treatment approaches for patients with nonmetastatic or metastatic bladder cancer that progresses on first-line therapy, based on optimal guideline recommended therapy sequence and assessment of patient and tumor factors that could affect efficacy; (3) Monitor patients with bladder cancer on immunotherapy, chemotherapy, or gene therapy for treatment-related adverse events, and employ optimal medical and pharmacologic management strategies; and (4) Counsel individual patients with non-metastatic or metastatic bladder cancer on the potential for enrollment on ongoing investigational clinical trial based on eligibility, due to failed therapeutic response, unique mechanism of action.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/bladder
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 0.0 - Is Kind Support: False Source: Pfizer (Any division) - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Community/Population Health, Learner Knowledge, Learner/Team Competence, Learner/Team Performance, Patient Health
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology